SCHEMBL4297883

SCHEMBL4297883

Nc1ccc(C(=O)Nc2ncc(Cl)s2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.58
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
LMNA P02545 2/20 0.56
RECQL P46063 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
STAT3 P40763 2/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA7 P43166 1/20 0.51
KDR P35968 1/20 0.49
TDP1 Q9NUW8 2/20 0.49
PKM P14618 2/20 0.49
APEX1 P27695 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290502 0.82 SMN1; SMN2 (0.71) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL4292546 0.81 KDR (0.59) ALOX15NPC1RAB9AMEN1KMT2A
SCHEMBL27727733 0.81 SMN1; SMN2 (0.55) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL4293155 0.80 STAT3 (0.64) ALOX15NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL27549855 0.78 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL5835822 0.78 CDK2 (0.75) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL27706901 0.77 NPC1 (0.55) NPC1RAB9ASMN1; SMN2LMNARECQL
SCHEMBL24072542 0.77 NPC1 (0.58) ALOX15NPC1RAB9ASMN1; SMN2STAT3
SCHEMBL30339193 0.77 NPC1 (0.58) ALOX15NPC1RAB9ASMN1; SMN2STAT3
SCHEMBL4292854 0.76 ADORA2A (0.63) ALOX15NPC1RAB9ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ALOX15 1975/4885NPC1 1022/4885RAB9A 2380/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ALOX15 1975/4885NPC1 1022/4885RAB9A 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.